scholarly journals Usefulness of the Exhaled Breath Temperature Plateau in Asthma Patients

Respiration ◽  
2015 ◽  
Vol 90 (2) ◽  
pp. 111-117 ◽  
Author(s):  
Astrid Crespo Lessmann ◽  
Jordi Giner ◽  
Alfons Torrego ◽  
Eder Mateus ◽  
Montserrat Torrejón ◽  
...  
Keyword(s):  
Exhaled Breath ◽  
Asthma Patients ◽  
Temperature Plateau

Detection and characterization of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients

2021 ◽  
pp. 2003024
Author(s):  
Donatella Lucchetti ◽  
Giuseppe Santini ◽  
Luigi Perelli ◽  
Claudio Ricciardi-Tenore ◽  
Filomena Colella ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Extracellular Vesicles ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Asthma Patients ◽  
Breath Condensate

Diagnosis and Management of Severe Asthma

2018 ◽  
Vol 39 (01) ◽  
pp. 091-099 ◽  
Author(s):  
Kian Fan Chung
Keyword(s):  
Severe Asthma ◽  
Inhaled Corticosteroids ◽  
Immunoglobulin E ◽  
High Dose ◽  
Blood Eosinophil ◽  
Exhaled Breath ◽  
Eosinophilic Asthma ◽  
Severe Eosinophilic Asthma ◽  
Asthma Patients ◽  
Long Acting

AbstractSevere therapy-resistant asthma has been defined as “asthma which requires treatment with high dose inhaled corticosteroids (ICSs) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ or which remains ‘uncontrolled’ despite this therapy”. Patients who usually present with ‘difficult-to-treat asthma’ should first be assessed to determine whether he/she has asthma with the exclusion of other diagnoses and if so, whether the asthma can be classified as severe therapy-resistant. This necessitates an assessment of adherence to medications, confounding factors, and comorbidities. Increasingly, management of severe therapy-resistant asthma will be helped by the determination of phenotypes to optimize responses to existing and new therapies. Severe asthma patients are usually on a combination of high dose ICS and long-acting β-agonist (LABA) and, in addition, are often on a maintenance dose of oral corticosteroids. Phenotyping can be informed by measuring blood eosinophil counts and the level of nitric oxide in exhaled breath, and the use of sputum granulocytic counts. Severe allergic asthma and severe eosinophilic asthma are two defined phenotypes for which there are efficacious targeted biologic therapies currently available, namely anti-immunoglobulin E (IgE) and anti-interleukin (IL)-5 antibodies, respectively. Further progress will be realized with the definition of noneosinophilic or non-T2 phenotypes. It will be important for patients with severe asthma to be ultimately investigated and managed in specialized severe asthma centers.

Concentrations of 15-HETE and PGE2 in Exhaled Breath Condensates of Asthma Patients

2008 ◽  
Vol 121 (2) ◽  
pp. S256-S256 ◽  
Author(s):  
K KOWAL ◽  
S ZUKOWSKI ◽  
O KOWALBIELECKA ◽  
A BODZENTALUKASZYK ◽  
L DUBUSKE
Keyword(s):  
Exhaled Breath ◽  
Asthma Patients

scholarly journals Inflammatory Markers and Acid-Base Equilibrium in Exhaled Breath Condensate of Stable and Unstable Asthma Patients

2012 ◽  
Vol 159 (2) ◽  
pp. 121-129 ◽  
Author(s):  
Maria Magdalena Tomasiak-Lozowska ◽  
Ziemowit Zietkowski ◽  
Katarzyna Przeslaw ◽  
Marian Tomasiak ◽  
Roman Skiepko ◽  
...  
Keyword(s):  
Inflammatory Markers ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Acid Base ◽  
Base Equilibrium ◽  
Acid Base Equilibrium ◽  
Asthma Patients ◽  
Breath Condensate

scholarly journals Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients.

2010 ◽  
Vol 11 (1) ◽  
Author(s):  
Ziemowit Zietkowski ◽  
Maria M Tomasiak-Lozowska ◽  
Roman Skiepko ◽  
Elzbieta Zietkowska ◽  
Anna Bodzenta-Lukaszyk
Keyword(s):  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Asthma Patients ◽  
Breath Condensate
Sign in / Sign up

Export Citation Format

Share Document